Papers
2
Total Citations
144
H-Index
2
About
Li Di is a distinguished pharmaceutical scientist whose research lies at the intersection of drug metabolism, pharmacokinetics, and high-throughput screening methodologies. With a career dedicated to advancing drug discovery workflows, Di has made significant contributions to the optimization of assay systems that help researchers evaluate the viability of drug candidates early in the development pipeline. Di's most influential work, "Optimization of a Higher Throughput Microsomal Stability Screening Assay for Profiling Drug Discovery Candidates" (2003), has garnered 137 citations, reflecting its lasting impact on how the pharmaceutical industry approaches metabolic stability profiling. This foundational study helped streamline the screening process, enabling faster and more cost-effective identification of promising compounds. More recently, Di has extended this expertise into cutting-edge multiplexed screening platforms, as demonstrated by a 2024 publication introducing novel high-throughput methods for identifying selective inhibitors of drug-metabolizing enzymes using human hepatocytes — a more physiologically relevant system that promises greater predictive accuracy. Spanning over two decades of productive research, Li Di's work continues to shape modern drug discovery practices, offering tools that bridge experimental efficiency with biological relevance and ultimately accelerating the path from bench to bedside.
Research Focus
Key Achievements
Top Papers
- 1
- 2